# US 2026/0235581 A1 · Method for the selection of an ecobiological compound capable of increasing the skin tolerance threshold

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0235581 A1
- Document ID: US20260235581A1
- Status: Published application
- Kind: A1
- Application number: 19/153,470
- Filed: 2024-02-19
- Published: 2026-08-13
- Earliest claimed: 2023-02-17
- Assignees: Jean-Noël THOREL
- Applicants: Naos Institute of Life Science
- Inventors: Jean-Noël THOREL
- Web page: https://patentgrep.com/patent/US20260235581A1

## CPC

- G01N 33/5044: {involving specific cell types}
- A61K 8/361: {Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/73: Polysaccharides
- A61Q 19/00: Preparations for care of the skin
- C12N 5/0698: {Skin equivalents}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/5055: {involving macrophages}
- G01N 33/5058: {Neurological cells}
- G01N 33/5088: {of vertebrates}
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/148: Screening for cosmetic compounds
- C12Q 2600/158: Expression markers
- G01N 2333/521: Chemokines
- G01N 2333/7158: for chemokines
- G01N 2800/20: Dermatological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method for the selection of at least one compound, preferably ecobiological, is provided, intended for the prevention and/or care of sensitive and/or sensitised skin, implementing the identification of a modulation of the content of TAFA4 and/or of nucleic acid encoding it.

## Claims

### Claim 1

A method for the selection of at least one compound intended for the prevention and/or care of sensitive and/or sensitized skin, implementing the identification of a modulation of the content of TAFA4 and/or nucleic acid.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said method comprises the following steps:
a) Bringing said at least one compound into contact with at least one skin cell;
b) Measuring the content of TAFA4 and/or of nucleic acid encoding TAFA4;
c) Comparing the value obtained in step b) with a reference value;
d) Selecting said at least one compound inducing an increase in the content of TAFA4 and/or of nucleic acid in step c).

### Claim 3 (depends on 2)

The method according to claim 2, wherein said reference value is the measurement obtained without bringing said at least one skin cell into contact with said at least one compound.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the said content of TAFA4 and/or nucleic acid encoding TAFA4 is measured in the intra- and/or extracellular medium of said at least one skin cell.

### Claim 5 (depends on 2)

The method according to claim 2, wherein:
an increase in the content of TAFA4 corresponds to at least 120% with respect to said reference value; and/or
an increase in the content of nucleic acid encoding TAFA4 corresponds to at least 120% with respect to said reference value.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the at least one compound is not the TAFA4 protein or one of its biologically active derivatives.

### Claim 7 (depends on 1)

The method according to any one of the preceding claim 1, wherein said method is an in vivo or ex vivo method and in that the bringing into contact of step a) is performed by topical application of said at least one compound to the skin of a whole living organism, a skin explant, a reconstructed epidermis or a reconstructed skin.

### Claim 8 (depends on 2)

The method according to claim 2, wherein:
this is an in vitro method,
said at least one skin cell is chosen from keratinocytes, melanocytes, sebocytes, Merkel cells, vascular smooth muscle cells, specialised muscle cells, fibroblasts, mastocytes, lymphocytes, monocytes, dendritic cells; Langerhans cells, adipocytes, nerve cells, macrophages; endothelial cells; and mixtures thereof; and
said bringing into contact of step a) is performed by adding into the culture medium.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the at least one skin cell is:
at least one macrophage; and/or
at least one keratinocyte; and/or
at least one fibroblast; and/or
at least one nerve cell.

### Claim 10 (depends on 2)

The method according to claim 2, wherein step b) of measuring the content of TAFA4 and/or of nucleic acid, encoding TAFA4 is carried out at a protein level by an ELISA test, immunohistochemistry, colorimetric method, western blot, dot blot or western simplified by capillary immunoelectrophoresis (WES) and/or at the nucleic level by in situ hybridisation, northern blot, sequencing or RT-PCR.

### Claim 11 (depends on 2)

The method according to claim 2, wherein, before the implementation of step a), said at least one skin cell has been brought into contact, by topical application or by adding into the culture medium, with a sensitising agent.

### Claim 12 (depends on 1)

The method according to claim 1, wherein:
the amino acid sequence of TAFA4 corresponds to the sequence SEQ ID NO: 1 and/or to SEQ ID NO: 2 and/or to a sequence identical to one of the sequences SEQ ID NO: 1 to 2 to at least 60%; and/or
the nucleotide sequence of TAFA4 corresponds to the sequence SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7 or to a sequence identical to one of the sequences SEQ ID NO: 3 to 7 to at least 60%.

### Claim 13 (depends on 1)

A method of formulating a cosmetic and/or food composition, non-therapeutic, comprising the incorporation into said composition of at least one compound selected by the method according to claim 1.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the compound is ecobiological.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the modulation is an increase of the content of TAFA4 and/or nucleic acid encoding TAFA4.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the modulation is an increase of the content of messenger ribonucleic acid (mRNA) encoding TAFA4.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the cosmetic and/or food composition, non-therapeutic is ecobiological.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the cosmetic and/or food composition, non-therapeutic is in a galenic form suitable for topical and/or oral administration.
